Group 1 - The core viewpoint of the articles highlights the performance of the Chinese medicine sector, particularly the 中证中药指数 (CSI Traditional Chinese Medicine Index), which shows mixed results among its constituent stocks, with 千金药业 (Qianjin Pharmaceutical) leading the gains at 1.92% [1] - 中药ETF (Traditional Chinese Medicine ETF) has seen a recent price of 0.99 yuan, with a net subscription of 2 million units during the trading session, indicating a continuous inflow for 30 days [1] - A significant study published in the journal "Phytomedicine" by a team from the China Academy of Chinese Medical Sciences demonstrates the clinical benefits of 中药复方新加达原散 (Xinjia Dayuan Powder) in improving microbial clearance rates, suggesting its potential as an auxiliary treatment option [1] Group 2 - 万联证券 (Wanlian Securities) recommends focusing on innovative drugs and devices, particularly in major fields such as oncology, autoimmune diseases, and metabolic disorders, as well as new technology platforms like ADCs and gene therapies [2] - The report emphasizes the importance of 中医药 (Traditional Chinese Medicine), particularly companies with strong brand moats and modernization capabilities, in light of supportive policies [2] - As of September 30, 2025, the top ten weighted stocks in the 中证中药指数 account for 55.08% of the index, with notable companies including 云南白药 (Yunnan Baiyao) and 片仔癀 (Pianzaihuang) [2]

（文章来源：新华社） 齐文升介绍，这项研究于2022年6月至2025年3月由广安门医院牵头，在4家中医医院进行，开展多中 心、随机、双盲对照临床试验；研究对象为患有多重耐药革兰氏阴性菌肺炎的成年住院患者，经筛选最 终有224名患者符合入选标准并完成随机分组。 此外，这项研究的整体安全性评估显示，新加达原散组与标准抗生素对照组的安全性相当。 北京中医药大学东直门医院急诊科主任吴彩军认为，新加达原散作为中药复方，在研究中展现出免疫调 节与抗炎作用，其在微生物学结局上的优势，结合良好的安全性，支持其未来可能作为多重耐药菌的辅 助治疗选择，给解决细菌耐药这一难题提供了临床治疗方案。 论文共同通讯作者之一、广安门医院急诊科副主任赵昕表示，团队将在这一成果基础上深入开展科研攻 关，上下求索，让中医药这个中华瑰宝在服务人民健康中发挥更大作用。 因治疗选择有限、死亡率高，多重耐药革兰氏阴性菌肺炎成为威胁患者生命的挑战。我国中医学者经过 两年多临床试验发现，中药可成为应对这类"超级细菌"的新选择。 记者24日从中国中医科学院广安门医院获悉，该院齐文升主任医师团队发现，中药复方新加达原散在提 高第7天的微生物学清除率等方面展现出 ...